Phreesia (NYSE:PHR) General Counsel Sells $18,116.28 in Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison Hoffman sold 1,106 shares of the stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $16.38, for a total value of $18,116.28. Following the completion of the sale, the general counsel owned 173,656 shares of the company’s stock, valued at $2,844,485.28. This trade represents a 0.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Phreesia Stock Down 3.8%

Shares of NYSE PHR traded down $0.63 during mid-day trading on Tuesday, reaching $15.76. 888,246 shares of the company’s stock were exchanged, compared to its average volume of 1,011,187. Phreesia, Inc. has a twelve month low of $15.41 and a twelve month high of $32.76. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $950.23 million, a price-to-earnings ratio of -157.59 and a beta of 0.61. The business has a fifty day simple moving average of $18.24 and a 200 day simple moving average of $23.18.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.11. The business had revenue of $120.33 million during the quarter, compared to analysts’ expectations of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.Phreesia’s revenue for the quarter was up 12.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.25) EPS. As a group, equities analysts expect that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Institutional Trading of Phreesia

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Moody National Bank Trust Division boosted its position in Phreesia by 63.8% during the fourth quarter. Moody National Bank Trust Division now owns 195,944 shares of the company’s stock valued at $3,315,000 after purchasing an additional 76,345 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Phreesia during the 4th quarter worth approximately $1,203,000. Diversified Trust Co. raised its stake in shares of Phreesia by 12.2% during the 4th quarter. Diversified Trust Co. now owns 51,422 shares of the company’s stock worth $870,000 after purchasing an additional 5,600 shares in the last quarter. Tudor Investment Corp ET AL acquired a new stake in shares of Phreesia in the 3rd quarter valued at approximately $4,173,000. Finally, FNY Investment Advisers LLC bought a new position in shares of Phreesia in the third quarter valued at $183,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Barclays cut their price objective on shares of Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 16th. Zacks Research lowered Phreesia from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. KeyCorp reduced their price objective on Phreesia from $35.00 to $32.00 and set an “overweight” rating for the company in a research report on Wednesday, October 8th. JPMorgan Chase & Co. dropped their target price on Phreesia from $32.00 to $29.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 9th. Finally, Canaccord Genuity Group cut their target price on Phreesia from $38.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, December 9th. Seventeen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $30.06.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.